Renal cell carcinoma in native kidneys before transplantation - When will we stop waiting?
https://doi.org/10.4081/aiua.2023.11240
Accepted: February 17, 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Introduction: Kidney transplantation requires immunosuppression, traditionally regarded as a risk factor for progression in all malignancies. Based on the Cincinnati Registry, a waiting period before transplantation is therefore mandatory. However, recent evidence suggests this increased risk is restricted to particular tumors, whereas others like renal cell carcinoma (RCC) are not negatively affected. We aimed to compare oncological outcomes of RCC in native kidneys of end-stage renal disease (ESRD) patients, according to their transplantation or dialysis status.
Material and methods: Retrospective analysis of all ESRD patients diagnosed with RCC between 2010 and 2020 in our center. Recurrence-free survival (RFS) and overall survival (OS) were estimated with Kaplan-Meier curves. Multivariable Cox regression model was used to evaluate their association with kidney transplantation.
Results: Clinical and pathological characteristics were similar between groups. Kidney transplant recipients had similar risk of recurrence (hazard ratio [HR] 0.40, 95% confidence interval [CI) 0.04-4.46, p = 0.458) and overall survival (HR 0.34, 95%CI 0.07-1.77, p = 0.202) as dialyzed patients. On multivariable Cox regression model, presence or absence of transplantation was not significantly associated with RFS (p = 0.479) or OS (p = 0.236). Time on dialysis was the only independent predictor of worse survival (HR 1.86, 95%CI 1.18-2.93, p = 0.008).
Conclusions: Most RCC in native kidneys of ESRD patients are low-grade, low-stage and exhibit favourable pathological and outcome features. Immunosuppression does not seem to have an impact on oncological outcomes, but an increased time on dialysis seems to be associated with worse overall survival. Therefore, waiting time for transplantation for these tumors could be reduced.
Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplanta- tion, and recipients of a first cadaveric transplant. N Engl J Med. 1999; 341:1725-1730. DOI: https://doi.org/10.1056/NEJM199912023412303
Farrugia D, Mahboob S, Cheshire J, et al. Malignancy-related mortality following kidney transplantation is common. Kidney Int. 2014; 85:1395-1403. DOI: https://doi.org/10.1038/ki.2013.458
Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant. 1997; 2:14-17.
Piselli P, Serraino D, Segoloni GP, et al. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur J Cancer. 2013; 49:336-344. DOI: https://doi.org/10.1016/j.ejca.2012.09.013
Kliem V, Kolditz M, Behrend M, et al. Risk of renal cell carcino- ma after kidney transplantation. Clin Transplant. 1997; 11:255- 258.
Yanik EL, Clarke CA, Snyder JJ, Pfeiffer RM, Engels EA. Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction Intervals. J Am Soc Nephrol. 2016; 27:1495-1504. DOI: https://doi.org/10.1681/ASN.2015040373
Moudouni SM, Lakmichi A, Tligui M, et al. Renal cell carcinoma of native kidney in renal transplant recipients. BJU Int. 2006; 98:298-302. DOI: https://doi.org/10.1111/j.1464-410X.2006.06267.x
Choyke PL. Acquired cystic kidney disease. Eur Radiol. 2000; 10:1716-1721. DOI: https://doi.org/10.1007/s003300000601
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17:1471-1474. DOI: https://doi.org/10.1245/s10434-010-0985-4
Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016; 70:93-105. DOI: https://doi.org/10.1016/j.eururo.2016.02.029
Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013; 37:1490-1504. DOI: https://doi.org/10.1097/PAS.0b013e318299f0fb
Kälble T, Lucan M, Nicita G, Sells R, Burgos Revilla FJ, Wiesel M. EAU guidelines on renal transplantation. Eur Urol. 2005; 47:156-166. DOI: https://doi.org/10.1016/j.eururo.2004.02.009
Brattström C, Granath F, Edgren G, et al. Overall and cause- specific mortality in transplant recipients with a pretransplantation cancer history. Transplantation. 2013; 96:297-305. DOI: https://doi.org/10.1097/TP.0b013e31829854b7
Viecelli AK, Lim WH, Macaskill P, et al. Cancer-Specific and All- Cause Mortality in Kidney Transplant Recipients With and Without Previous Cancer. Transplantation. 2015; 99:2586-2592. DOI: https://doi.org/10.1097/TP.0000000000000760
Dahle DO, Grotmol T, Leivestad T, et al. Association Between Pretransplant Cancer and Survival in Kidney Transplant Recipients. Transplantation. 2017; 101:2599-2605. DOI: https://doi.org/10.1097/TP.0000000000001659
Johansen KL, Chertow GM, Foley RN, et al. US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2021; 77(4 Suppl 1):A7-a8. DOI: https://doi.org/10.1053/j.ajkd.2021.01.002
Au EH, Chapman JR, Craig JC, et al. Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant. J Am Soc Nephrol. 2019; 30:471-480. DOI: https://doi.org/10.1681/ASN.2018090906
Gigante M, Neuzillet Y, Patard JJ, et al. Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities? BJU Int. 2012; 110:E570-573. DOI: https://doi.org/10.1111/j.1464-410X.2012.11273.x
Klatte T, Seitz C, Waldert M, et al. Features and outcomes of renal cell carcinoma of native kidneys in renal transplant recipients. BJU Int. 2010; 105:1260-1265. DOI: https://doi.org/10.1111/j.1464-410X.2009.08941.x
Boissier R, Hevia V, Bruins HM, et al. The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End- stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review. Eur Urol. 2018; 73:94-108. DOI: https://doi.org/10.1016/j.eururo.2017.07.017
Breda A, Lucarelli G, Rodriguez-Faba O, et al. Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kid- neys of patients with end-stage renal disease: a long-term compara- tive retrospective study with RCC diagnosed in the general popula- tion. World J Urol. 2015; 33:1-7. DOI: https://doi.org/10.1007/s00345-014-1248-y
Tsuzuki T, Iwata H, Murase Y, et al. Renal tumors in end-stage renal disease: A comprehensive review. Int J Urol. 2018; 25:780- 786. DOI: https://doi.org/10.1111/iju.13759
Chen WJ, Pan CC, Shen SH, et al. Clear cell papillary renal cell carcinoma - An indolent subtype of renal tumor. J Chin Med Assoc. 2018; 81:878-883. DOI: https://doi.org/10.1016/j.jcma.2018.04.005
Denton MD, Magee CC, Ovuworie C, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a patho- logic analysis. Kidney Int. 2002; 61:2201-2209. DOI: https://doi.org/10.1046/j.1523-1755.2002.00374.x
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
